Table 2. Summary of association results with combined data from all stages of study.a .
| Primary | Replication | ||||||||
| SNP | Gene | A1/A2 | FrCase/FrCont | P | OR | FrCase/FrCont | P | OR | Comb. P |
| n = 23/n = 101 | n = 16/n = 265 | ||||||||
| Chr6.24500625 | RBBP6 | T/G | 0.91/0.38 | 1.98E–10 | 16.32 | 0.69/0.41 | 0.0019 | 3.20 | 1.01E–9 |
| (5.62–47.41) | (1.49–6.89) | ||||||||
| Chr6.25681850 | USP31 | G/T | 0.98/0.31 | 3.24E–16 | 97.98 | 0.72/0.23 | 8.57E–10 | 8.55 | 6.16E–22 |
| (13.19–727.90) | (3.85–18.96) | ||||||||
| Chr6.25714052 | USP31 | G/A | 0.98/0.74 | 0.0012 | 13.52 | 0.91/0.71 | 0.016 | 3.96 | 0.00015 |
| (1.81–100.90) | (1.19–13.19) | ||||||||
a
SNP: marker name (location information); A1: risk allele; A2: reference allele; FrCase: allele frequency of A1 in cases; FrCont: allele frequency of A1 in controls; P: p-values from allelic association analysis; OR: odds ratio with 95% confidence interval; Comb. P: combined p-value from meta-analysis.
The strength of association of the three variants is shown. Chr6.24500625 in RBBP6 and Chr6.25681850 in USP31 remain highly significant after inclusion of more cases and controls.